Fairmount Funds Management LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Fairmount Funds Management LLC disclosed 12 US equity positions worth $1.4bn in its Q1 2026 13F filing. The largest position was DMRA at 16.3% of the reported book, followed by DNTH and COGT.
What did Fairmount Funds Management LLC own in Q1 2026? Top 12 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 16.3% | $225.7m | 8,713,000 | – | |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 15.4% | $212.9m | 2,537,191 | – | |
| 3 | COGT COGENT BIOSCIENCES INC | Healthcare | 15.3% | $211.8m | 5,503,418 | – | |
| 4 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 14.6% | $202.7m | 4,018,101 | – | |
| 5 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 13.1% | $181.7m | 3,705,262 | – | |
| 6 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 5.5% | $76.6m | 3,914,458 | – | |
| 7 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 5.3% | $72.7m | 1,855,644 | – | |
| 8 | JBIO JADE BIOSCIENCES INC | Healthcare | 4.6% | $64.0m | 4,553,494 | – | |
| 9 | CBIO CRESCENT BIOPHARMA INC. | 3.6% | $50.5m | 2,747,866 | – | ||
| 10 | ZBIO ZENAS BIOPHARMA INC | 3.3% | $46.1m | 2,359,025 | – | ||
| 11 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.8% | $25.1m | 298,647 | – | |
| 12 | IKT INHIBIKASE THERAPEUTICS INC | 1.0% | $14.5m | 8,625,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.